The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-syste...

Autores
Gennari, Laura; Blanco, Alicia; Alberto, Maria Fabiana; Grosso, Silvia; Lazzari, María Ángela
Año de publicación
2003
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus erythematosus (SLE) patients, which was furthermore associated with venous thromboembolism. The acquired APCR phenotype occurs in the absence of the factor V (FV) Leiden mutationand has been described among patients with antiphospholipid antibodies (APA).There is no clear information about which antibodies are involved in this phenotype. However, an in vitro effect of theanti-b2-glycoprotein I (ab2GPI) antibodies on the response to activated protein C (APC) has been described (Matsuda et al, 1995; Martinuzzo et al, 1996; Galli et al, 1998).We evaluated whether the presence of ACA immunoglobulin (Ig)G and ab2GPI IgG was associated with acquired APCR in 24 LA patients with primary antiphospholipid syndrome.
Fil: Gennari, Laura. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Blanco, Alicia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Grosso, Silvia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Materia
ACA IGG ANTIBODIES
ACQUIRED APCR
ANTIΒ2GPI IGG ANTIBODIES
LUPUS ANTICOAGULANT
NON-SLE PATIENTS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/66644
Acceder
id CONICETDig_fd9ee3809bc550f67ef630efc71e9036
oai_identifier_str oai:ri.conicet.gov.ar:11336/66644
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patientsGennari, LauraBlanco, AliciaAlberto, Maria FabianaGrosso, SilviaLazzari, María ÁngelaACA IGG ANTIBODIESACQUIRED APCRANTIΒ2GPI IGG ANTIBODIESLUPUS ANTICOAGULANTNON-SLE PATIENTShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus erythematosus (SLE) patients, which was furthermore associated with venous thromboembolism. The acquired APCR phenotype occurs in the absence of the factor V (FV) Leiden mutationand has been described among patients with antiphospholipid antibodies (APA).There is no clear information about which antibodies are involved in this phenotype. However, an in vitro effect of theanti-b2-glycoprotein I (ab2GPI) antibodies on the response to activated protein C (APC) has been described (Matsuda et al, 1995; Martinuzzo et al, 1996; Galli et al, 1998).We evaluated whether the presence of ACA immunoglobulin (Ig)G and ab2GPI IgG was associated with acquired APCR in 24 LA patients with primary antiphospholipid syndrome.Fil: Gennari, Laura. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; ArgentinaFil: Blanco, Alicia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; ArgentinaFil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; ArgentinaFil: Grosso, Silvia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; ArgentinaFil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; ArgentinaWiley Blackwell Publishing, Inc2003-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/66644Gennari, Laura; Blanco, Alicia; Alberto, Maria Fabiana; Grosso, Silvia; Lazzari, María Ángela; The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 121; 3; 5-2003; 527-5290007-1048CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1046/j.1365-2141.2003.04304.xinfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04304.xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:04:59Zoai:ri.conicet.gov.ar:11336/66644instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:04:59.676CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
title The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
spellingShingle The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
Gennari, Laura
ACA IGG ANTIBODIES
ACQUIRED APCR
ANTIΒ2GPI IGG ANTIBODIES
LUPUS ANTICOAGULANT
NON-SLE PATIENTS
title_short The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
title_full The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
title_fullStr The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
title_full_unstemmed The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
title_sort The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
dc.creator.none.fl_str_mv Gennari, Laura
Blanco, Alicia
Alberto, Maria Fabiana
Grosso, Silvia
Lazzari, María Ángela
author Gennari, Laura
author_facet Gennari, Laura
Blanco, Alicia
Alberto, Maria Fabiana
Grosso, Silvia
Lazzari, María Ángela
author_role author
author2 Blanco, Alicia
Alberto, Maria Fabiana
Grosso, Silvia
Lazzari, María Ángela
author2_role author
author
author
author
dc.subject.none.fl_str_mv ACA IGG ANTIBODIES
ACQUIRED APCR
ANTIΒ2GPI IGG ANTIBODIES
LUPUS ANTICOAGULANT
NON-SLE PATIENTS
topic ACA IGG ANTIBODIES
ACQUIRED APCR
ANTIΒ2GPI IGG ANTIBODIES
LUPUS ANTICOAGULANT
NON-SLE PATIENTS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus erythematosus (SLE) patients, which was furthermore associated with venous thromboembolism. The acquired APCR phenotype occurs in the absence of the factor V (FV) Leiden mutationand has been described among patients with antiphospholipid antibodies (APA).There is no clear information about which antibodies are involved in this phenotype. However, an in vitro effect of theanti-b2-glycoprotein I (ab2GPI) antibodies on the response to activated protein C (APC) has been described (Matsuda et al, 1995; Martinuzzo et al, 1996; Galli et al, 1998).We evaluated whether the presence of ACA immunoglobulin (Ig)G and ab2GPI IgG was associated with acquired APCR in 24 LA patients with primary antiphospholipid syndrome.
Fil: Gennari, Laura. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Blanco, Alicia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Grosso, Silvia. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
Fil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas ; Argentina
description Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus erythematosus (SLE) patients, which was furthermore associated with venous thromboembolism. The acquired APCR phenotype occurs in the absence of the factor V (FV) Leiden mutationand has been described among patients with antiphospholipid antibodies (APA).There is no clear information about which antibodies are involved in this phenotype. However, an in vitro effect of theanti-b2-glycoprotein I (ab2GPI) antibodies on the response to activated protein C (APC) has been described (Matsuda et al, 1995; Martinuzzo et al, 1996; Galli et al, 1998).We evaluated whether the presence of ACA immunoglobulin (Ig)G and ab2GPI IgG was associated with acquired APCR in 24 LA patients with primary antiphospholipid syndrome.
publishDate 2003
dc.date.none.fl_str_mv 2003-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/66644
Gennari, Laura; Blanco, Alicia; Alberto, Maria Fabiana; Grosso, Silvia; Lazzari, María Ángela; The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 121; 3; 5-2003; 527-529
0007-1048
CONICET Digital
CONICET
url http://hdl.handle.net/11336/66644
identifier_str_mv Gennari, Laura; Blanco, Alicia; Alberto, Maria Fabiana; Grosso, Silvia; Lazzari, María Ángela; The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 121; 3; 5-2003; 527-529
0007-1048
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1046/j.1365-2141.2003.04304.x
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04304.x
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781318558384128
score 12.982451

Publicaciones similares